Learn how you can stall the development of full-blown Multiple Myeloma with evidence-based nutritional and supplementation therapies.
Click the orange button to the right to learn more.
“Our study confirms that WB MRI detects skeletal disease in a higher number of treatment-naïve (Multiple Myeloma) patients than PET/CT..”
The study linked and excerpted below is studying the sensitivity of both MRI and PET/CT detecting “skeletal disease” in multiple myeloma patients. Fine. But what about detecting bone disease in pre-multiple myeloma. Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)?
Let me explain.
You have been diagnosed with either a
By itself, none of these diagnostic terms is that worrisome. Pre-MM is not cancer, they are blood disorders. The worrisome issue, in my opinion anyway, is that pre-mm can become full-blown MM. According to research, the risk of MGUS becoming MM is 1% annually and the risk of SMM becoming MM is 10% for the first three years, 3% for years 4-10 and 1% after year 10.
It is the risk of pre-MM becoming frank MM that is the issue. I believe the study below can give you key info to help determine your risk of your pre-MM becoming frank MM.
Your m-spike can go up and down. Your immunoglobulins, free light chains, blood cells, all can go up and down. But bone involvement, monoclonal proteins IN your bone marrow, that is important to determine.
If you have been diagnosed with pre-MM, talk to your oncologist about whole body MRI (WBMRI).
If you are interested in learning more about evidence-based therapies shown to reduce the risk of MM, scroll down the page, post a question or comment and I will reply to you ASAP.
“This study compared the diagnostic performance and impact on management of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) and whole-body magnetic resonance imaging (WBMRI) in treatment-naive myeloma…
Blinded clinical and imaging data were reviewed by two haematologists in consensus and management recorded following clinical data ± 18F-FDG PET/CT or WBMRI. Bone disease was defined using International Myeloma Working Group (IMWG) criteria and a clinical reference standard. Per-patient sensitivity for lesion detection was established. McNemar test compared management based on clinical assessment ± 18F-FDG PET/CT or WBMRI…
Sensitivity for bone lesions was 69.6% (32/46) for 18F-FDG PET/CT (54.3% (25/46) for PET component alone) and 91.3% (42/46) for WBMRI. 27/46 (58.7%) of cases were concordant.
In 19/46 patients (41.3%) WBMRI detected more focal bone lesions than 18F-FDG PET/CT. Based on clinical data alone, 32/46 (69.6%) patients would have been treated. Addition of 18F-FDG PET/CT to clinical data increased this to 40/46 (87.0%) patients (p = 0.02); and WBMRI to clinical data to 43/46 (93.5%) patients (p = 0.002).
The difference in treatment decisions was not statistically significant between 18F-FDG PET/CT and WBMRI (p = 0.08)…
Compared to 18F-FDG PET/CT, WBMRI had a higher per patient sensitivity for bone disease.
However, treatment decisions were not statistically different and either modality would be appropriate in initial staging, depending on local availability and expertise…
A small number of studies, with limited sample sizes, have compared the diagnostic accuracy of 18F-FDG PET/CT and WBMRI in myeloma [2,3,4,5], but to date, there has been a lack of comparative data of the impact on management of 18F-FDG PET/CT and WBMRI.
Additionally, in patients with smouldering myeloma, the presence of >1 focal bone lesion detected by WBMRI  or the presence of a focal FDG-avid lesion  is a strong prognostic factor for progression to myeloma such that they are now recognised as an indication to treat otherwise asymptomatic myeloma [12, 13]…
…We hypothesised that the greater sensitivity of WBMRI for detection of myeloma compared to 18F-FDG PET/CT would alter patient management in a greater proportion of cases. Thus, the primary aim of this study was to compare the diagnostic performance of 18F-FDG PET/CT and WBMRI for bone disease in patients with a new myeloma diagnosis and to assess whether management differed depending on which imaging was performed initially…
There was moderate agreement between the two readers in scoring for the presence/absence of focal CT and PET disease, with a kappa score of 0.44 and 0.47, respectively. Identification of CT disease was discordant in 3/12 patients, where CT positive but FDG-negative lesions were noted by one reader. Identification of FDG-positive disease was also discordant in 3/12 patients.
There was excellent agreement between the two readers in scoring for the presence/absence of focal lesions on a per patient basis (kappa score, 1.00). With respect to the scoring of the number of lesions across the 7 regions, mean ± SD focal lesion score was 7.4 ± 5.7 for Reader 1 and 7.7 ± 5.5 for Reader 2; with an intraclass correlation coefficient of 0.95 [95%CI: 0.84-0.99].
With respect to the presence/absence of bone marrow infiltration, there was good agreement between both readers with a kappa score of 0.74; one patient with a bone marrow infiltration percentage of 90% on biopsy was assigned incorrectly as negative by one reader…
Impact on clinical management
Based on the review of clinical data alone, 32/46 (69.6%) of patients would be treated for myeloma rather than active surveillance, in accordance with institutional treatment protocols. Review of clinical data with 18F-FDG PET/CT resulted in treatment of 40/46 (87.0%) patients, and review of clinical data with WBMRI resulted in treatment of 43/46 (93.5%) patients…
Our study confirms that WBMRI detects skeletal disease in a higher number of treatment-naïve patients than 18F-FDG PET/CT and also detects a higher number of lesions per patient with concordance in disease positivity/lesion number in only 59% of patients…